Substance Use Risk and Solution-Focused Approach

December 9, 2024 updated by: Ufuk DOĞAN

The Effect of Solution-Focused Approach on the Self-Control and Substance Use Risk Level of Nursing Students with Substance Use Risk

Although substance abuse is the subject of serious struggles on the basis of individuals and countries, its rate of spread cannot be stopped and it creates an agenda with new people added every day. Substance addiction, which not only creates physiological problems in individuals, but also affects human health in every aspect with psychological and social problems, adversely affects the health status of individuals as well as their families and environments. The best way to get rid of addiction is to never start. Therefore, our study focused on preventing addiction, not addiction. After applying the Substance Use Tendency Scale and Self-Control Scale to university students, an intervention and control group will be formed. Solution Focused Approach program will be applied to the intervention group. At the end of the program, post-tests will be applied to the intervention and control groups.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

First of all, the Substance Use Tendency Scale (MDAS) and personal information form will be applied to the nursing students of the Faculty of Health Sciences, which consists of 750 people. A high score in any of the BCAS subscales indicates a tendency towards addiction. After this, students with a tendency will be determined. After the power analysis is performed, the appropriate number of samples will be determined. Finally, participants will be assigned to the intervention/control group by randomization. A substance use prevention psychoeducation program based on a solution-focused approach will be applied to the experimental group in 7 sessions for 6 weeks. No intervention will be made to the control group. At the end of psychoeducation, posttests will be collected from the experimental and control groups.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
40

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Elazığ, Turkey, 23000
        • Ufuk Doğan

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

The criteria for inclusion in the research at the stage;

  • Being an active student registered as a nursing student at Fırat University
  • Volunteering to participate in the research.
  • Not receiving any psychological counseling and treatment
  • Getting a sufficiently high score in any of the sub-dimensions according to the Substance Use Risk Profile Scale
  • Not being diagnosed with substance abuse or substance abuse Exclusion criteria from the study at Phase I;
  • Not complying with the principle of volunteering
  • Getting a low score in all sub-dimensions according to the Substance Use Risk Profile Scale
  • Being diagnosed with substance abuse or substance abuse

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
No Intervention: Control Group
Experimental: Experimental Group
The "short solution-oriented program" intervention group will be applied for 6 weeks, a total of 7 lesson hours.
Other: Short Solution Focused Approach Program
It will be a psychoeducational approach aimed at developing preventive and protective properties against addiction.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Changes in Students' Substance Use Risk Levels
Time Frame: 3 month period
The scale developed by Woicik et al. (2009) and showing good psychometric properties in non-clinical samples was validated and reliability-tested in Turkish by Uygun et al. (2019). It is a 23-item (4-point Likert scale: 1 strongly disagree, 4 strongly agree) measurement tool. The scale has four subdimensions: hopelessness/self-discontent, impulsivity, sensation seeking, and anxiety sensitivity. The Cronbach's alpha value is determined to be 0.728. If at least one of the subscale scores is found to be high, it indicates a high risk of substance use in the individua
3 month period
"Changes in the Self-Control Levels of Students at Risk of Substance Use
Time Frame: 3 month period
The Self-Control Scale (SCS): The scale was developed by Rosenbaum in 1980. It measures how well individuals can use their existing control behaviors to solve problems they encounter in daily life. The Turkish validity and reliability studies were conducted by Duyan, Gülden, and Gelbal in 2012. The scale aims to estimate individuals' mental skills in controlling psychological and physiological responses such as anxiety, anger, and pain; delaying short-term satisfaction; initiating problem-solving processes; and self-efficacy perception. The scale consists of 3 sub-dimensions: Restorative Self-Control, Experiential Self-Control, and Renewing Self-Control, with a total of 36 items. Participants are asked to select one of the options prepared in a 6-point Likert type ranging from "Completely fits me +3" to "Completely does not fit me -3" in response to the questions. Higher scores on the scale indicate higher levels of self-control. The Cronbach's Alpha value was found to be 0.809.
3 month period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Ufuk DOĞAN

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Ufuk Doğan, PhD, Hasan Kalyoncu University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 1, 2023

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 1, 2023

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 30, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 29, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 9, 2024

First Posted (Estimated)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
December 13, 2024

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
December 13, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 9, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
December 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2023/69

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings